Based on ratings from 15 stock analysts, the Integra LifeSciences Holdings Corp stock price is expected to increase by 39.42% in 12 months. This is calculated by using the average 12-month stock price forecast for Integra LifeSciences Holdings Corp. The lowest target is $16 and the highest is $40. Please note analyst price targets are not guaranteed and could be missed completely.
IART is a stock in Healthcare which has been forecasted to be worth $26.88 as an average. On the higher end, the forecast price is $40 USD by from Jefferies and on the lower end IART is forecasted to be $16 by Joanne Wuensch from Citigroup.
These are the latest 20 analyst ratings of IART.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Richard Newitter Truist Securities | Hold | $21 | Maintains | Oct 14, 2024 |
Craig Bijou B of A Securities | Underperform | $18 | Maintains | Oct 7, 2024 |
Ryan Zimmerman BTIG | Neutral | Upgrade | Oct 7, 2024 | |
Joanne Wuensch Citigroup | Sell | $16 | Maintains | Oct 1, 2024 |
Ryan Zimmerman BTIG | Sell | $20 | Maintains | Aug 28, 2024 |
Joanne Wuensch Citigroup | Sell | $20 | Maintains | Aug 22, 2024 |
Ryan Zimmerman BTIG | Sell | $22 | Downgrade | Jul 30, 2024 |
Richard Newitter Truist Securities | Hold | $26 | Maintains | Jul 30, 2024 |
Joanne Wuensch Citigroup | Sell | $23 | Downgrade | Jul 30, 2024 |
David Turkaly JMP Securities | Market Outperform | $35 | Maintains | Jul 30, 2024 |
Richard Newitter Truist Securities | Hold | $32 | Maintains | Jul 16, 2024 |
Drew Ranieri Morgan Stanley | Underweight | $27 | Maintains | Jul 15, 2024 |
Citigroup | Neutral | Maintains | Jul 11, 2024 | |
Joanne Wuensch Citigroup | Neutral | $30 | Maintains | Jul 10, 2024 |
Joanne Wuensch Citigroup | Neutral | $28 | Maintains | May 22, 2024 |
Drew Ranieri Morgan Stanley | Underweight | $24 | Maintains | May 7, 2024 |
David Turkaly JMP Securities | Market Outperform | $40 | Maintains | May 7, 2024 |
Craig Bijou B of A Securities | Underperform | $26 | Maintains | May 7, 2024 |
Richard Newitter Truist Securities | Hold | $25 | Maintains | May 7, 2024 |
Vik Chopra Wells Fargo | Equal-Weight | $25 | Downgrade | May 7, 2024 |
When did it IPO
1995
Staff Count
3,946
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Jan De Witte
Market Cap
$1.46B
In 2023, IART generated $1.54B in revenue, which was a decrease of -1.03% from the previous year. This can be seen as a signal that IART's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Integra LifeSciences (NASDAQ: IART) will release Q3 2024 financial results on November 4, 2024, before market open, followed by a conference call at 8:30 a.m. ET.
Why It Matters - Integra LifeSciences' upcoming earnings report may influence stock price and investor sentiment, providing insights into financial health and growth prospects within the medical technology sector.
Summary - Integra's strong growth in the Tissue Technologies and CSS segments has enhanced investor confidence in the stock.
Why It Matters - Integra's growth in key business segments signals robust demand and potential for increased revenue, enhancing stock appeal and encouraging investment.
Summary - Kaskela Law LLC is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) following a securities fraud complaint related to shareholder purchases from March 2019 to May 2023.
Why It Matters - The investigation into Integra LifeSciences over alleged securities fraud may signal potential legal and financial risks, impacting share prices and investor confidence.
Summary - Integra LifeSciences (IART) CFO Lea Knight will present at the Wells Fargo Healthcare conference on September 4, 2024, at 1:30 PM ET.
Why It Matters - Lea Knight's presentation at a major healthcare conference could signal strategic insights or updates for Integra LifeSciences, influencing stock performance and investor sentiment.
Summary - Integra LifeSciences (NASDAQ: IART) CFO Lea Knight will present at the Morgan Stanley Healthcare conference on September 6, 2024, at 10:45 AM ET.
Why It Matters - Integra LifeSciencesโ CFO presenting at a major healthcare conference signals potential strategic insights and growth prospects, influencing investor sentiment and stock performance.
Summary - The company released its third ESG report, highlighting its values and commitment to restoring lives, which may impact its reputation and investor perception.
Why It Matters - The third ESG report highlights the company's dedication to sustainability and social responsibility, potentially attracting socially conscious investors and enhancing its market reputation.